Home LiteratureArticle Details
PMID: 19080728 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Apolipoprotein A-I mimetic peptides.

Current atherosclerosis reports ·Vol. 11 ·No. 1 ·2009-01-00 ·Pages 52-7

Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, Buga GM, Fogelman AM

Abstract

Recent publications reveal the mechanism of action of apolipoprotein A-I (apoA-I) mimetic peptides to be the remarkable binding affinity that oxidized lipids have for these peptides compared with apoA-I. There was no difference in the binding affinity of oxidized lipids or in peptide efficacy in reducing inflammation and atherosclerosis in rabbits injected with peptides synthesized from all D- or all L-amino acids. The apoA-I mimetic peptide 4F increased the formation of pre-beta high-density lipoprotein, increased cholesterol efflux, and reduced lipoprotein oxidation in vitro; it increased antioxidants and vascular repair in type 1 diabetic rats; it improved vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in a mouse model of scleroderma; it reduced renal inflammation in low-density lipoprotein receptor-null mice fed a Western diet; it reduced arthritis in a rat model; it reduced adiposity, increased adiponectin levels, and improved insulin sensitivity in obese mice; and it improved high-density lipoprotein inflammatory properties in humans with coronary heart disease.

MeSH Terms
Animals Anti-Inflammatory Agents/pharmacology,therapeutic use Apolipoprotein A-I/pharmacology,therapeutic use Arthritis/drug therapy Atherosclerosis/prevention & control Cholesterol, HDL/blood Diabetes Mellitus/drug therapy Disease Models, Animal Humans Hyperlipidemias/complications Nephritis/drug therapy,etiology Obesity/drug therapy Scleroderma, Systemic/drug therapy
Chemicals
Anti-Inflammatory Agents Apolipoprotein A-I Cholesterol, HDL
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Van Lenten Brian J
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. [email protected]
Wagner Alan C
Anantharamaiah G M
Navab Mohamad
Reddy Srinivasa T
Buga Georgette M
Fogelman Alan M
References (16)
16 references, click to expand
  1. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet.
    J Lipid Res. 2008 Jan;49(1):192-205 PMID: 17925450
  2. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Circulation. 2004 Jun 29;109(25):3215-20 PMID: 15197147
  3. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.
    J Am Coll Cardiol. 2008 Jun 10;51(23):2199-211 PMID: 18534265
  4. Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats.
    J Pharmacol Exp Ther. 2007 Aug;322(2):514-20 PMID: 17488882
  5. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.
    J Lipid Res. 2000 Sep;41(9):1495-508 PMID: 10974057
  6. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice.
    Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1432-41 PMID: 17496220
  7. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.
    J Lipid Res. 2008 Aug;49(8):1658-69 PMID: 18426778
  8. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits.
    J Lipid Res. 2007 Nov;48(11):2344-53 PMID: 17693626
  9. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.
    Clin Immunol. 2008 May;127(2):234-44 PMID: 18337176
  10. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.
    J Lipid Res. 2001 Jul;42(7):1096-104 PMID: 11441137
  11. Apolipoprotein A-I mimetic peptides.
    Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1325-31 PMID: 15831812
  12. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
    J Lipid Res. 2007 Sep;48(9):1915-23 PMID: 17570869
  13. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.
    J Lipid Res. 2008 Jun;49(6):1344-52 PMID: 18323573
  14. An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma.
    J Lipid Res. 2008 Mar;49(3):581-7 PMID: 18056684
  15. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.
    J Lipid Res. 2008 Nov;49(11):2302-11 PMID: 18621920
  16. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
    J Lipid Res. 2008 Jun;49(6):1268-83 PMID: 18323574
Article Info
Journal
Current atherosclerosis reports
Abbr.
Curr Atheroscler Rep
ISSN
1534-6242
Published
2009-01-00
Pages
52-7
Language
English
Region
United States
NLM ID
100897685
PMCID
PMC2856617
Subset
IM
Grants
NHLBI NIH HHS · HL-34343 · United States
NHLBI NIH HHS · P01 HL034343-110009 · United States
NHLBI NIH HHS · P01 HL030568-26A1 · United States
NHLBI NIH HHS · P01 HL030568 · United States
NHLBI NIH HHS · HL-30568 · United States
NHLBI NIH HHS · P01 HL034343 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]